Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04667494 · ClinicalTrials.gov registry record · Phase 4

Ultrasound Therapy In Cardiac Amyloidosis

A Phase 4 study of Amyloidosis Cardiac, sponsored by Brigham and Women's Hospital.

Recruiting
Registry status
Phase 4
Development phase
70
Enrollment target
1
Study location

NCT04667494 is a Phase 4 study of Amyloidosis Cardiac that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 70 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04667494, a Phase 4 study of Amyloidosis Cardiac, is actively recruiting participants, sponsored by Brigham and Women's Hospital.

RECRUITING
Registry status
Phase 4
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow, systolic and diastolic function before and after sonotherapy.

Conditions Studied

Interventions

  • COMBINATION_PRODUCT Sonotherapy

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2023-08-31
Est. Completion 2027-04-30
Phase Phase 4

Sponsor

Brigham and Women's Hospital

937 total trials

What the Registry Record Tells You About NCT04667494

The ClinicalTrials.gov registry entry for NCT04667494 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Amyloidosis Cardiac appearing as the primary indexed condition, and to 1 intervention - of which Sonotherapy is the first listed.

NCT04667494 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04667494 about?

NCT04667494 is a clinical study titled "Ultrasound Therapy In Cardiac Amyloidosis". This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow, systolic and diastolic function before and after sonotherapy.

What is the current status of trial NCT04667494?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2023-08-31. Estimated completion is 2027-04-30.

What conditions does trial NCT04667494 study?

This clinical trial studies the following conditions: Amyloidosis Cardiac.

What interventions are being tested in trial NCT04667494?

The interventions under investigation include: Sonotherapy (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT04667494?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04667494 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyloidosis Cardiac

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.